2Seventy Bio Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $260.90 million
- Book Value:
- Revenue TTM:
- $147.25 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
2Seventy Bio Inc had its IPO on 2021-11-03 under the ticker symbol TSVT.
The company operates in the Healthcare sector and Biotechnology industry. 2Seventy Bio Inc has a staff strength of 425 employees.
Shares of 2Seventy Bio Inc opened at $4.6 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.1 - $4.6, and closed at $4.16.
This is a -5.02% slip from the previous day's closing price.
A total volume of 2,064,060 shares were traded at the close of the day’s session.
In the last one week, shares of 2Seventy Bio Inc have slipped by -19.54%.
2Seventy Bio Inc's Key Ratios
2Seventy Bio Inc has a market cap of $260.90 million, indicating a price to book ratio of 1.4431 and a price to sales ratio of 8.24.
In the last 12-months 2Seventy Bio Inc’s revenue was $147.25 million with a gross profit of $-183458000 and an EBITDA of $-185862000. The EBITDA ratio measures 2Seventy Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, 2Seventy Bio Inc’s operating margin was -132.46% while its return on assets stood at -16.33% with a return of equity of -48.26%.
In Q2, 2Seventy Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 167.4%.
2Seventy Bio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 2Seventy Bio Inc’s profitability.
2Seventy Bio Inc stock is trading at a EV to sales ratio of 9.064 and a EV to EBITDA ratio of -2.0768. Its price to sales ratio in the trailing 12-months stood at 8.24.
2Seventy Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $705.71 million
- Total Liabilities
- $66.90 million
- Operating Cash Flow
- Capital Expenditure
- $3.97 million
- Dividend Payout Ratio
2Seventy Bio Inc ended 2023 with $705.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $705.71 million while shareholder equity stood at $367.50 million.
2Seventy Bio Inc ended 2023 with $0 in deferred long-term liabilities, $66.90 million in other current liabilities, 5000.00 in common stock, $-382757000.00 in retained earnings and $12.06 million in goodwill. Its cash balance stood at $95.99 million and cash and short-term investments were $282.84 million. The company’s total short-term debt was $11,872,000 while long-term debt stood at $0.
2Seventy Bio Inc’s total current assets stands at $333.67 million while long-term investments were $23.71 million and short-term investments were $186.85 million. Its net receivables were $44.10 million compared to accounts payable of $6.27 million and inventory worth $-44099000.00.
In 2023, 2Seventy Bio Inc's operating cash flow was $-64881000.00 while its capital expenditure stood at $3.97 million.
Comparatively, 2Seventy Bio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
2Seventy Bio Inc stock is currently trading at $4.16 per share. It touched a 52-week high of $17.56 and a 52-week low of $17.56. Analysts tracking the stock have a 12-month average target price of $24.33.
Its 50-day moving average was $7.34 and 200-day moving average was $10.28 The short ratio stood at 5.21 indicating a short percent outstanding of 0%.
Around 165.6% of the company’s stock are held by insiders while 10171.6% are held by institutions.
Frequently Asked Questions About 2Seventy Bio Inc
Similar Industry Stocks (Biotechnology)
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.